IN2014MN02487A - - Google Patents
Info
- Publication number
- IN2014MN02487A IN2014MN02487A IN2487MUN2014A IN2014MN02487A IN 2014MN02487 A IN2014MN02487 A IN 2014MN02487A IN 2487MUN2014 A IN2487MUN2014 A IN 2487MUN2014A IN 2014MN02487 A IN2014MN02487 A IN 2014MN02487A
- Authority
- IN
- India
- Prior art keywords
- pharmaceutical composition
- adhesive free
- present
- excipient
- granular
- Prior art date
Links
- 239000000853 adhesive Substances 0.000 abstract 3
- 230000001070 adhesive effect Effects 0.000 abstract 3
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 2
- 239000008186 active pharmaceutical agent Substances 0.000 abstract 1
- 230000000840 anti-viral effect Effects 0.000 abstract 1
- 230000004888 barrier function Effects 0.000 abstract 1
- 239000011248 coating agent Substances 0.000 abstract 1
- 238000000576 coating method Methods 0.000 abstract 1
- 229960000980 entecavir Drugs 0.000 abstract 1
- YXPVEXCTPGULBZ-WQYNNSOESA-N entecavir hydrate Chemical compound O.C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)C1=C YXPVEXCTPGULBZ-WQYNNSOESA-N 0.000 abstract 1
- 239000008187 granular material Substances 0.000 abstract 1
- 208000002672 hepatitis B Diseases 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 239000008203 oral pharmaceutical composition Substances 0.000 abstract 1
- 229940124531 pharmaceutical excipient Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
- A61J3/10—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of compressed tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
- A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Virology (AREA)
- Oncology (AREA)
- Biotechnology (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA 2779052 CA2779052A1 (en) | 2012-05-31 | 2012-05-31 | Pharmaceutical composition of entecavir and process of manufacturing |
| PCT/CA2013/000517 WO2013177672A1 (en) | 2012-05-31 | 2013-05-28 | Pharmaceutical composition of entecavir and process of manufacturing |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014MN02487A true IN2014MN02487A (enExample) | 2015-07-17 |
Family
ID=49672225
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN2487MUN2014 IN2014MN02487A (enExample) | 2012-05-31 | 2013-05-28 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US20150110869A1 (enExample) |
| EP (1) | EP2854773B1 (enExample) |
| JP (1) | JP6320371B2 (enExample) |
| KR (1) | KR20150015500A (enExample) |
| CN (1) | CN104363896A (enExample) |
| CA (2) | CA2779052A1 (enExample) |
| HK (1) | HK1208620A1 (enExample) |
| IN (1) | IN2014MN02487A (enExample) |
| WO (1) | WO2013177672A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201610636VA (en) | 2014-06-20 | 2017-01-27 | Ctc Bio Inc | Pharmaceutical preparation containing entecavir as active ingredient, and preparation method therefor |
| CN104473896B (zh) * | 2014-12-01 | 2017-04-19 | 东莞市金美济药业有限公司 | 一种快速崩解的拉米夫定片及其制备工艺 |
| EP3478286B1 (en) | 2016-06-29 | 2024-01-03 | Tesaro, Inc. | Methods of treating ovarian cancer |
| MX2019011496A (es) | 2017-03-27 | 2020-01-23 | Tesaro Inc | Composiciones de niraparib. |
| EP3606523A1 (en) * | 2017-03-27 | 2020-02-12 | Tesaro, Inc. | Niraparib formulations |
| BR112020006039A2 (pt) | 2017-09-26 | 2020-10-06 | Tesaro, Inc. | formulações de niraparibe |
| CN109550020A (zh) * | 2019-02-14 | 2019-04-02 | 任连智 | 一种治疗乙肝大小三阳的药物制剂及制备方法 |
| CN110354129A (zh) * | 2019-08-19 | 2019-10-22 | 苏州扬厉医药科技有限公司 | 一种治疗乙肝病毒的新药药物组合及制备方法 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2401569C (en) * | 2000-02-29 | 2009-08-18 | Bristol-Myers Squibb Company | Low dose entecavir formulation and use |
| CA2311734C (en) * | 2000-04-12 | 2011-03-08 | Bristol-Myers Squibb Company | Flash-melt oral dosage formulation |
| WO2004000265A2 (en) * | 2002-06-24 | 2003-12-31 | Ranbaxy Laboratories Limited | Process for the preparation of robust formulations of valacyclovir hydrochloride tablets |
| US7905852B2 (en) * | 2006-05-16 | 2011-03-15 | Barbara Jennings-Spring | Skin-contacting-adhesive free dressing |
| US20070281000A1 (en) * | 2006-06-02 | 2007-12-06 | Michael Fox | Stable formulation comprising moisture sensitive drug/s and manufacturing procedure thereof |
| CN101245068A (zh) * | 2007-02-14 | 2008-08-20 | 浙江医药股份有限公司新昌制药厂 | 结晶型态的恩替卡韦及其制备方法和其药物组合物及用途 |
| WO2009106954A1 (en) * | 2008-02-27 | 2009-09-03 | Aurobindo Pharma Limited | Stable dosage forms of lamivudine and tenofovir |
| WO2009106960A2 (en) * | 2008-02-27 | 2009-09-03 | Aurobindo Pharma Limited | Stable compositions of lamivudine, tenofovir and efavirenz |
| WO2011009961A1 (en) * | 2009-07-24 | 2011-01-27 | Virologik Gmbh | Combination of proteasome inhibitors and anti-hepatitis medication for treating hepatitis |
| EA201290556A1 (ru) * | 2009-12-23 | 2013-01-30 | Рациофарм Гмбх | Оральная лекарственная форма, включающая энтекавир |
| ES2524408T5 (es) * | 2010-11-19 | 2022-04-25 | Gilead Sciences Inc | Composiciones terapéuticas que comprenden rilpivirina HCl y tenofovir disoproxil fumarato |
| EP2508172A1 (en) * | 2011-04-06 | 2012-10-10 | Zentiva, a.s. | Stable and uniform formulations of entecavir and preparation method thereof |
| US20140315930A1 (en) * | 2011-11-14 | 2014-10-23 | Hetero Research Foundation | Fast release solid oral compositions of entecavir |
| WO2013114389A1 (en) * | 2011-12-21 | 2013-08-08 | Mylan Laboratories Limited. | Process for preparing solid oral formulations comprising low dose of entecavir |
-
2012
- 2012-05-31 CA CA 2779052 patent/CA2779052A1/en not_active Abandoned
-
2013
- 2013-05-28 HK HK15109146.7A patent/HK1208620A1/xx unknown
- 2013-05-28 EP EP13797878.9A patent/EP2854773B1/en active Active
- 2013-05-28 JP JP2015514297A patent/JP6320371B2/ja active Active
- 2013-05-28 CN CN201380030696.6A patent/CN104363896A/zh active Pending
- 2013-05-28 CA CA2874779A patent/CA2874779C/en active Active
- 2013-05-28 US US14/404,176 patent/US20150110869A1/en not_active Abandoned
- 2013-05-28 WO PCT/CA2013/000517 patent/WO2013177672A1/en not_active Ceased
- 2013-05-28 IN IN2487MUN2014 patent/IN2014MN02487A/en unknown
- 2013-05-28 KR KR20147034899A patent/KR20150015500A/ko not_active Ceased
-
2018
- 2018-04-03 US US15/944,452 patent/US20190076366A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CA2874779C (en) | 2019-03-05 |
| CA2779052A1 (en) | 2013-11-30 |
| JP6320371B2 (ja) | 2018-05-09 |
| JP2015521191A (ja) | 2015-07-27 |
| CA2874779A1 (en) | 2013-12-05 |
| US20190076366A1 (en) | 2019-03-14 |
| KR20150015500A (ko) | 2015-02-10 |
| HK1208620A1 (en) | 2016-03-11 |
| CN104363896A (zh) | 2015-02-18 |
| WO2013177672A1 (en) | 2013-12-05 |
| US20150110869A1 (en) | 2015-04-23 |
| EP2854773A4 (en) | 2016-01-27 |
| EP2854773B1 (en) | 2020-05-06 |
| EP2854773A1 (en) | 2015-04-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2014MN02487A (enExample) | ||
| AU2018256602A1 (en) | Functionalized benzamide derivatives as antiviral agents against hbv infection | |
| PH12018550148A1 (en) | Hepatitis b antiviral agents | |
| EA201592256A1 (ru) | Производные имидазопирролидинона и их применение при лечении заболеваний | |
| EA201592250A1 (ru) | Пиразолопирролидиновые производные и их применение в лечение заболеваний | |
| ME02150B (me) | Derivati piperidinona kao inhibitori mdm2 za lečenje kancera | |
| WO2011106729A3 (en) | Pharmaceutical compositions of spiro-oxindole compound for topical administration and their use as therapeutic agents | |
| MD4736B1 (ro) | Compus policiclic de carbamoilpiridonă şi utilizarea farmaceutică a acestuia | |
| NZ739248A (en) | Inhibitors of hepatitis c virus | |
| WO2009123776A3 (en) | Antiviral drugs for treatment of arenavirus infection | |
| WO2013147649A3 (ru) | ИНГИБИТОРЫ СИГНАЛЬНОГО ПУТИ PI3K/AKT/IKK/NF-kB, ИХ ФАРМАЦЕВТИЧЕСКИ ПРИЕМЛЕМЫЕ СОЛИ И СОДЕРЖАЩИЕ ИХ КОМПОЗИЦИИ ДЛЯ ПРОФИЛАКТИКИ И ЛЕЧЕНИЯ ВИРУСНЫХ ЗАБОЛЕВАНИЙ | |
| MX2013001757A (es) | Uso de aglutinantes para fabricar formulaciones estables al almacenamiento | |
| WO2017083304A8 (en) | Therapeutic compositions for treatment of human immunodeficiency virus | |
| EA201592255A1 (ru) | Производные пиразолопирролидин-4-она в качестве ингибиторов вет и их применение при лечении заболевания | |
| PH12012502083A1 (en) | Manufacturing of active-free granules and tablets comprising the same | |
| TN2011000651A1 (en) | Solid pharmaceutical fixed dose compositions comprising irbesartan and amlodipine their preparation and their therapeutic application | |
| WO2013022243A3 (ko) | 신규한 바이페닐 유도체 또는 이의 약학적으로 허용가능한 염, 및 이를 유효성분으로 포함하는 염증성 질환 또는 자가면역질환의 예방 또는 치료용 약학적 조성물 | |
| HRP20221344T1 (hr) | Novi pripravak acetaminofenskog spoja bez nuspojave po jetru | |
| GR1008821B (el) | Φαρμακευτικο σκευασμα που περιλαμβανει υδροχλωρικη ιβαμπραδινη και μεθοδος παρασκευης αυτου | |
| GR1008228B (el) | Φαρμακευτικο σκευασμα περιεχον ενα διπλο αναστολεα επαναπροσληψης και μεθοδος για την παρασκευη αυτου | |
| TR201310724A2 (tr) | Linagliptinin farmasotik formulasyonları. | |
| EP2593460A4 (en) | 7,9-NITROGEN-RADIKAL-4-OXO-4H-PYRIDO- [L, 2-A-] PYRIMIDIN-2-CARBOXYLIC ACID BENZYLAMIDE VIROSTATIKA | |
| LT3882244T (lt) | Junginys, farmaciniu požiūriu priimtina jo druska arba optinis jo izomeras, jo gamybos būdas, farmacinė kompozicija, kurios sudėtyje jis yra kaip veiklioji sudedamoji dalis, skirta virusinių ligų profilaktikai arba gydymui | |
| IN2011CH03893A (enExample) | ||
| PH12014501601A1 (en) | Artemisinin-based combination therapy for treating viral mediated disease |